A coeliac blood test can begin a diagnosis, but the word “positive” does not always finish it. In 2025, European guidance widened the possibility of diagnosis without a biopsy for selected adults. Understanding who qualifies, and why a negative result can still need investigation, matters more than treating an antibody number as a verdict on your gut.
What the first blood sample is looking for
Coeliac testing looks for an immune response, rather than measuring how well someone tolerates a particular meal. The NIDDK explanation of coeliac tests identifies tissue transglutaminase IgA, usually shortened to tTG-IgA, as the preferred antibody test for most patients. IgA describes the antibody class. Total IgA provides a different piece of information: whether that class is present in sufficient amounts for an IgA-based result to be useful.
If someone has IgA deficiency, clinicians may use IgG-based testing instead. This is why a report containing several unfamiliar abbreviations is not necessarily evidence of unnecessary testing. The tests can answer different questions. It is also why comparing an isolated result with someone else’s screenshot can mislead: the antibody type and laboratory interpretation belong alongside the number.
The same NIDDK guidance stresses that accurate testing requires a gluten-containing diet. That condition is part of interpreting the result, rather than an optional detail to disclose afterwards. A blood sample taken after dietary restriction may answer a different question from the one the clinician intended.
Why the symptoms and history still matter
The NIDDK patient guide to diagnosis describes assessment using medical and family history, examination, and test results. Symptoms alone cannot distinguish coeliac disease reliably from other digestive conditions. Conversely, a familiar label such as irritable bowel syndrome does not make a later assessment unnecessary if the clinical picture warrants one.
Coeliac disease also has a wider presentation than diarrhoea after bread. The NHS account of symptoms includes fatigue, unexpected weight loss, and neurological features such as tingling or problems with balance. These are reasons for clinical assessment, not a checklist with which to diagnose yourself. They can have other causes, and a coeliac test should not replace the investigation of those possibilities.
For someone trying to understand a result, the useful starting point is the question that prompted it. Was there persistent digestive trouble, unexplained anaemia, or a family history? The history supplies context that a laboratory flag cannot contain. Bringing that history back into the conversation is often more useful than ordering another broad private panel.
A negative result sometimes needs another look
NHS diagnostic guidance explicitly recognises that some people with coeliac disease do not have detectable antibodies. Persistent symptoms can therefore justify specialist referral despite a negative blood test. This does not mean that negative results are generally untrustworthy. It means their interpretation depends on the circumstances.
Before calling the result reassuring, the clinical team may need to establish whether gluten had already been reduced and whether the appropriate antibody pathway was used. A result cannot be separated from how the sample was obtained. The appropriate response to continuing symptoms is reassessment of the whole picture, including alternative diagnoses.
If you already avoid gluten, tell the clinician before testing is planned. Do not restart it independently to make a test work, particularly if food has caused a serious reaction or severe symptoms. Planning an investigation is a clinical discussion; it is not a home challenge. People with an established coeliac diagnosis should continue their agreed treatment rather than reintroducing gluten because they are curious about a blood result.
What the accuracy research actually measures
A 2022 systematic review in Alimentary Pharmacology & Therapeutics, led by Athena Sheppard, included 113 studies and 28,338 participants. It compared antibody tests against duodenal biopsy. All the included studies came from secondary care, an important limit when applying the findings to people first presenting in general practice.
Sensitivity describes how often a test identifies people who have the disease; specificity describes how often it correctly excludes people without it. Neither means that a positive result gives an individual the same percentage chance of having coeliac disease. That depends also on how likely disease was before testing.
The review found that thresholds varied, limiting which studies could be pooled. Its authors called for primary-care research and further work on interpreting results in sequence or combination. A useful test can therefore coexist with uncertainty about the best diagnostic pathway. The evidence supports thoughtful use of serology, rather than treating every result just above a cut-off as equivalent to a strongly positive one.
When a biopsy may still be part of the answer
Abdulbaqi Al-Toma and colleagues’ 2025 European Society for the Study of Coeliac Disease guideline in the United European Gastroenterology Journal conditionally supports diagnosis without biopsy in selected adults under 45 whose IgA anti-TG2 result is at least ten times the laboratory’s upper limit of normal. Confirmation in a second blood sample is required. Anti-TG2 is another name for the tissue-transglutaminase antibody discussed above.
The same guideline rules out this route when warning signs point towards another condition, including blood in the stool, difficulty swallowing, or signs of bowel obstruction. In secondary care, the decision to omit biopsy must be shared with the patient after discussing its advantages and limitations. Age and antibody concentration alone do not establish eligibility.
For this pathway, the guideline requires a gluten-containing diet to continue until confirmatory testing, with dietary preparation agreed with the clinician. Anyone who has already restricted gluten needs an individual plan rather than restarting it independently; the precautions above still apply.
This is a defined specialist pathway, not permission to diagnose yourself from one high result. It also should not be read as a universal UK rule: the NHS patient pathway describes specialist assessment and possible biopsy after positive antibodies. The team responsible for the investigation can explain which pathway applies locally and why.
When biopsy is needed, small samples from the small-intestinal lining are examined. NIDDK describes obtaining these during upper gastrointestinal endoscopy. Antibodies and tissue findings provide different kinds of evidence; needing both is not necessarily a contradiction. The important question is whether the available evidence establishes a sufficiently secure diagnosis for the decisions that follow.
Genetic testing answers a narrower question
A genetic result is easily mistaken for a diagnosis because it appears permanent and precise. NIDDK explains that HLA-DQ2 or HLA-DQ8 variants can help clarify difficult cases. Their absence makes coeliac disease very unlikely. Their presence does not establish it: most people carrying these variants do not develop the condition.
The useful distinction is between susceptibility and evidence of current disease. A positive genetic result cannot replace the rest of an assessment, and a commercial report is not a reason by itself to begin lifelong restriction. In an uncertain case, the clinician can explain whether genetic testing would change the next decision.
What this means in practice
- Keep a copy of the complete report, including antibody type, units, reference range, and any total IgA result, for the clinical discussion.
- Tell the team about gluten restriction before they interpret a negative result or plan further tests. Agree any dietary preparation with them.
- If symptoms persist, ask what the negative result excludes and what other explanations still need assessment.
- After a positive result, ask whether specialist confirmation, another sample, or biopsy is required in your pathway.
- If coeliac disease is already diagnosed, continue the agreed plan. NHS treatment guidance describes gluten avoidance with dietetic support; this article does not change that advice.
What we don’t know
We cannot assume that every assay, threshold, and clinical setting performs identically. The 2022 review’s hospital-based evidence leaves uncertainty about direct application in general practice. The 2025 European no-biopsy recommendation is conditional and applies to a selected group, rather than settling the pathway for every adult.
A good diagnostic process should leave the person with more than an abnormal flag: an explanation of what is established, what remains uncertain, and who will resolve it. That is where a blood test becomes useful care.
Photo: Ivan S on Pexels. Illustrative laboratory photograph.
